CCC 2023
Diet Plays Vital Role in IBD Care
Food can have a direct effect on inflammation and disease activity in IBD, making diet and nutrition a critical ...
AUGUST 23, 2023

For De-escalation of IBD Therapy, New Data Support Stopping Immunomodulators
If de-escalating IBD therapy, cutting out the immunomodulator but keeping the anti-TNF agent may be the best bet, ...
JULY 31, 2023

Benefits and Challenges of Apps, Digital Therapeutics in IBD Patient Care
Healthcare apps have made it easier than ever for patients to access information about their health, but it also ...
APRIL 28, 2023

Lower Heart Rate Variability Linked to Increased Fatigue in IBD Patients
Fatigue has been found to be correlated with lower heart rate variability, according to a study presented at the ...
APRIL 26, 2023

Redo IPAA Surgery Has Long-Term Benefits, Survey Says
Patients who undergo redo ileal pouch–anal anastomosis surgery can expect sustained quality of life for ...
APRIL 25, 2023

Using Telemedicine, Biomarkers and Imaging for IBD Monitoring
at the 2023 Crohn’s and Colitis Congress, experts presented approaches to IBD monitoring that offer hope for ...
APRIL 21, 2023

Impact of AI on the Future of Patient Care
As AI continues to reshape healthcare, it is crucial that healthcare professionals take a proactive approach to ...
APRIL 14, 2023

10 Clinical Pearls for Optimizing Outcomes in Ulcerative Colitis
UC requires a comprehensive approach that considers the individual needs and circumstances of each patient.
APRIL 13, 2023

Biologic Delays Are Common and Costly in Crohn’s Disease
Guideline recommendations for earlier initiation of biologics with Crohn’s disease are not always heeded in ...
MARCH 24, 2023

Dual-Targeted Therapy in IBD Not Yet Ready for Prime Time
More evidence on the safety and efficacy of dual-targeted therapy for IBD is needed, according to presentations at ...
MARCH 20, 2023

Report From CCC 2023: Real-World Data Help Optimize Tofacitinib Maintenance in Ulcerative Colitis
Dose de-escalation of tofacitinib appears to be safe and effective for patients with ulcerative colitis, but ...
JANUARY 23, 2023

Report From CCC 2023: Switching to Infliximab Biosimilar Safe for Adolescents, Young Adults With IBD
Adolescents and young adults with inflammatory bowel disease can switch from the originator to a biosimilar of ...
JANUARY 20, 2023
